Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to evaluate the anti-tumor activity of the combination of experimental drug (larotaxel) when combined with Herceptin® in patients with advanced breast cancer. Anti-tumor activity will be determined by looking at changes in tumor size on CT or MRI scans. Additional goals of this study are to look at patient safety, to determine how long the study drugs (larotaxel and Herceptin®) stay in the patient's body and what effects the study medications may have on each other, and to find out how long patients remain cancer free on this study treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnosis of breast cancer
- Evidence that cancer has spread beyond its original location or has come back and cannot be removed by surgery
- No more than one prior treatment for advanced disease
- Her2 positive status
- Adequate liver and kidney function
- No remaining severe harmful effects to prior treatments
Exclusion criteria
- Certain heart condition
- Pregnant Women
- History of another cancer except some skin cancers and cervical cancer
- Taking other treatments for your cancer at the time you enter the trial
Trial design
Primary purpose
Allocation
Interventional model
Masking
6 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal